Research and Markets: Staphylococcus Aureus Infections - Pipeline Review, H2 2013 Report

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/7tqxhk/staphylococcus) has announced the addition of the "Staphylococcus Aureus Infections - Pipeline Review, H2 2013" report to their offering.

'Staphylococcus Aureus Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Staphylococcus Aureus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Staphylococcus Aureus Infections.

Scope

- A snapshot of the global therapeutic scenario for Staphylococcus Aureus Infections.

- A review of the Staphylococcus Aureus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Staphylococcus Aureus Infections pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Key Topics Covered:

Introduction

Staphylococcus Aureus Infections Overview

Therapeutics Development

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Staphylococcus Aureus Infections - Therapeutics Assessment

Drug Profiles

lysostaphin - Drug Profile

WCK-771 - Drug Profile

avarofloxacin hydrochloride - Drug Profile

PF-06290510 - Drug Profile

P-128 - Drug Profile

GSK-2392106A - Drug Profile

STEBVax - Drug Profile

GSK-2392105A - Drug Profile

GSK-2392103A - Drug Profile

GSK-2392019A - Drug Profile

NDV-3 Vaccine - Drug Profile

SASPject PT1.2 - Drug Profile

GSK-2392102A - Drug Profile

Staphylococcus Aureus Vaccine - Drug Profile

MEDI-4893 - Drug Profile

MORAb-048 - Drug Profile

gallium citrate Ga 67 - Drug Profile

Staphylococcus Aureus Vaccine - Drug Profile

NVC-727 - Drug Profile

SEB-HIG - Drug Profile

SEB-HuMab - Drug Profile

Bactericidal Venom-Based Polypeptides - Drug Profile

MGB-BP-3 - Drug Profile

Second Generation Oxas - Drug Profile

Novarifyn - Drug Profile

AQP-182 - Drug Profile

niacinamide - Drug Profile

Vaccine For Staphylococcus - Drug Profile

and many more.....

Featured News & Press Releases

Appendix

List of Tables

List of Figures

Some of the Companies Mentioned

AstraZeneca PLC

GlaxoSmithKline plc

Genentech, Inc.

Daiichi Sankyo Company, Limited

Merck & Co., Inc.

Exploit Technologies Pte Ltd

Imaxio

Novartis AG

Actelion Ltd

Pfizer Inc.

Wockhardt Limited

NovaBay Pharmaceuticals, Inc.

Patrys Limited

Galapagos NV

Microbio Co., Ltd.

Morphotek, Inc.

Bharat Biotech International Limited

Novabiotics Ltd

GlycoVaxyn AG

Priaxon AG

Aquapharm Biodiscovery Limited

Aridis Pharmaceuticals LLC

For more information visit http://www.researchandmarkets.com/research/7tqxhk/staphylococcus

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Infectious Diseases

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Infectious Diseases